1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC

Authors

Utsav Joshi, Hematology/Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA
Suman Gaire, Department of Internal Medicine, Mount Sinai Chicago, Chicago, IL, USA.
Sumeet K. Yadav, Department of Hospital Internal Medicine, Mayo Clinic, Mankato, MN, 56001, USA.
Pravash Budhathoki, Bronxcare Health Sytem
Cheng Niu, Rochester Regional HealthFollow
Soon K. Low, Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
V Agrawal, Epidemiology, University of South Florida, Tampa, FL, USA
M Shafique, Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, FL, USA

Department

Internal Medicine

Document Type

Conference Proceeding

Publication Title

Annals of Oncology

Conference Name

European Society for Medical Oncology (ESMO) Congress

Conference Date

2024-09-13 - 2024-09-17

First Page

S848

DOI

10.1016/j.annonc.2024.08.1394

Volume

35

Issue

Supplement 2

Publication Date

9-1-2024

Recommended Citation

Joshi, U., Gaire, S., Yadav, S. K., Budhathoki, P., Niu, C., Low, S. K., Agrawal, V., & Shafique, M. (2024). 1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC. Annals of Oncology, 35 (Supplement 2), S848. https://doi.org/10.1016/j.annonc.2024.08.1394